Investment analysts at BMO Capital Markets upped their target price on shares of Boston Scientific Corp. (NYSE:BSX) from $10.00 to $11.00 in a note issued to investors on Friday, Analyst Ratings Net reports. The firm currently has a “market perform” rating on the stock. BMO Capital Markets’ target price suggests a potential downside of 5.34% from the stock’s previous close.
Boston Scientific Corp. (NYSE:BSX) traded up 0.69% on Friday, hitting $11.62. 16,792,788 shares of the company’s stock traded hands. Boston Scientific Corp. has a 52-week low of $5.04 and a 52-week high of $12.16. The stock has a 50-day moving average of $11. and a 200-day moving average of $9.12. The company’s market cap is $15.604 billion.
Boston Scientific Corp. (NYSE:BSX) last announced its earnings results on Thursday, October 24th. The company reported $0.17 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.09 by $0.08. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.73 billion. During the same quarter in the prior year, the company posted $0.16 earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis. Analysts expect that Boston Scientific Corp. will post $0.44 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Barclays raised their price target on shares of Boston Scientific Corp. from $12.00 to $13.00 in a research note to investors on Friday. They now have an “overweight” rating on the stock. Separately, analysts at Deutsche Bank raised their price target on shares of Boston Scientific Corp. from $11.00 to $13.00 in a research note to investors on Friday. They now have a “hold” rating on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Boston Scientific Corp. from $10.00 to $12.00 in a research note to investors on Friday. They now have a “hold” rating on the stock. Fifteen research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $10.10.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.